The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular ...

Supported by grants from the Deutsche Forschungsgemeinschaft, a grant (80735240) from the Deutsche Krebshilfe, the Else Kröner Fresenius Stiftung, the Else Kröner Clinician Scientist Program Munich: ...

The CMS Innovation Center is approaching the next negotiation cycle for the CGT Access Model. Several considerations will guide the selection of future candidate diseases and potential new model ...

Type 1 diabetes is characterized by an absolute insulin deficiency and immune dysregulation. Nearly one in three persons with type 1 diabetes will go on to have diabetic kidney disease, 1 an ...

Abstract To the Editor: In their article on the DREAMM-7 trial, Hungria and colleagues (Aug. 1 issue) 1 describe the treatment of patients with multiple myeloma that had progressed after at least one ...

A 49-year-old woman presented with a 6-month history of an itchy lump on her vulva. Examination showed a painless purple mass originating in the labia minora on the left side.

This Sounding Board announces a new FDA policy that the default requirement for FDA approvals will be one robust pivotal trial plus confirmatory evidence, rather than two trials.

Trainees’ paths to safe, independent practice are variable. Artificial intelligence could help accelerate implementation of competency-based medical education to support individualized development.

Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may ...

Private equity firms have gained increasing control of U.S. health care infrastructure. Along with other potential consequences, this growth threatens to undermine progress in health equity.

Progress in the treatment of relapsed or refractory multiple myeloma has been rapid since the introduction of T-cell–redirecting immunotherapies. The identification of B-cell maturation antigen (BCMA) ...

Abstract The ratio of $50,000 per quality-adjusted life-year (QALY) gained by using a given health care intervention has long served as a benchmark for the value of U.S. health care. But evidence ...